Difference between revisions of "Motixafortide (Aphexda)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
| + | ==Mechanism of action== | ||
cyclic-peptide CXCR4 inhibitor | cyclic-peptide CXCR4 inhibitor | ||
| − | + | *[https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10679 IUPHAR/BPS] | |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*2023-09-12: Approved for the mobilization of hematopoietic stem cells to peripheral blood prior to collection for autologous stem cell transplantation (ASCT) in patients with multiple myeloma. ''(Based on GENESIS)'' | *2023-09-12: Approved for the mobilization of hematopoietic stem cells to peripheral blood prior to collection for autologous stem cell transplantation (ASCT) in patients with multiple myeloma. ''(Based on GENESIS)'' | ||
==Also known as== | ==Also known as== | ||
| + | *'''Code names:''' BKT-140, BL-8040, TF-14016 | ||
*'''Brand name:''' Aphexda | *'''Brand name:''' Aphexda | ||
Latest revision as of 15:23, 17 November 2023
Mechanism of action
cyclic-peptide CXCR4 inhibitor
History of changes in FDA indication
- 2023-09-12: Approved for the mobilization of hematopoietic stem cells to peripheral blood prior to collection for autologous stem cell transplantation (ASCT) in patients with multiple myeloma. (Based on GENESIS)
Also known as
- Code names: BKT-140, BL-8040, TF-14016
- Brand name: Aphexda